We have demonstrated that both strategies hamper cancer cell viability and self-renewal capacity and confirmed that the concept of synthetically lethal interactions of HMOX1 and FH genes might be an attractive option for the treatment of HLRCC-associated tumors. The gene discussed is HMOX1; the disease is hereditary leiomyomatosis and renal cell cancer.